Detalhe da pesquisa
1.
Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024.
MMWR Morb Mortal Wkly Rep
; 73(9): 209-214, 2024 Mar 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38457312
2.
Respiratory Syncytial Virus-Associated Hospitalizations Among Children <5 Years Old: 2016 to 2020.
Pediatrics
; 153(3)2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38298053